The global mass spectrometry market size was estimated at USD 6.6 billion in 2024 and is projected to reach USD 10.65 billion by 2030, growing at a CAGR of 7.97% from 2025 to 2030. This strong growth trajectory is primarily attributed to the increasing investments in research and development (R&D) within the pharmaceutical and biotechnology industries, which are major end-users of mass spectrometry technology.

Mass spectrometers are becoming indispensable in these sectors for their ability to deliver precise molecular analysis, facilitate drug discovery, and ensure stringent quality control standards. As pharmaceutical companies continue to invest heavily in developing new therapeutics and biologics, the demand for reliable analytical tools like mass spectrometry (MS) is growing significantly. A notable example includes Merck & Co., which has directed considerable R&D resources toward drug development, resulting in increased usage of MS for tasks such as protein characterization and biomarker discovery.

Further supporting the market's expansion are advances in proteomics research and the rapid evolution of biomedical science, both of which require high-performance analytical platforms. Proteomics, in particular, relies heavily on mass spectrometry to identify and quantify proteins in complex biological samples, which is crucial for understanding disease mechanisms and developing targeted therapies.

Technological innovations are also playing a key role in market growth. Recent trends include the integration of artificial intelligence (AI) into MS platforms to enhance data analysis, improve speed, and increase the accuracy of results. The development of high-resolution mass spectrometers, such as Orbitrap and Quadrupole Time-of-Flight (Q-TOF) systems, has further elevated the capabilities of MS by offering superior sensitivity and the ability to analyze highly complex samples with greater precision.

Additionally, government funding and policy support aimed at advancing the pharmaceutical and healthcare sectors are fueling demand for MS technologies. Increased public investment facilitates cutting-edge R&D initiatives in areas such as drug discovery, diagnostics, and personalized medicine. These investments create favorable conditions for the adoption of mass spectrometry, as the technology plays a critical role in enabling scientific breakthroughs and regulatory compliance.

Key Market Trends & Insights:

• In 2024, North America emerged as the dominant regional market in the global mass spectrometry industry, accounting for a substantial revenue share of 41.63%. This leadership position can be attributed to advanced research infrastructure, strong investment in life sciences, and widespread adoption of cutting-edge analytical technologies across various sectors, including pharmaceuticals, biotechnology, and healthcare.

• Within the region, the United States contributed a significant share to the North American mass spectrometry market in 2024. The U.S. has a strong presence of key industry players, leading academic institutions, and pharmaceutical companies that are heavily involved in research and development. These factors, coupled with favorable government funding and regulatory frameworks, have driven the widespread use of mass spectrometry technologies across the country.

• Based on product type, the instruments segment dominated the market in 2024, generating the largest revenue share. This segment is also projected to grow at a notable compound annual growth rate (CAGR) of 7.28%, driven by increasing demand for high-precision instruments used in molecular analysis, clinical diagnostics, and quality control. Continuous technological advancements, along with the need for high-throughput and sensitive analytical tools, are supporting the sustained growth of this segment.

• In terms of technology, the quadrupole liquid chromatography-mass spectrometry (LC-MS) segment led the market in 2024, accounting for the largest market share of 37.3%. This dominance is due to the technology's versatility, high sensitivity, and precision in detecting and quantifying compounds in complex samples. Quadrupole LC-MS is widely used in pharmaceutical analysis, clinical research, environmental testing, and food safety, making it a preferred choice across a variety of applications.

• By application, the proteomics segment held the largest market share, accounting for 46.21% in 2024. The growing focus on personalized medicine, biomarker discovery, and protein-based disease research has significantly increased the use of mass spectrometry in proteomics. The ability of MS to accurately identify and quantify proteins in complex biological samples makes it an indispensable tool for proteomic research, especially in academic and clinical settings.

Order a free sample PDF of the Mass Spectrometry Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 6.6 Billion

• 2030 Projected Market Size: USD 10.65 Billion

• CAGR (2025-2030): 7.97%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The market exhibits a high level of competition, driven by a variety of strategic initiatives implemented by leading players aiming to strengthen their position and expand their presence worldwide. Key companies are actively engaging in new product launches, which involve the introduction of innovative mass spectrometry (MS) technologies designed to meet evolving customer needs and improve analytical performance. Alongside product innovation, mergers and acquisitions are frequently pursued as strategic moves to enhance technological capabilities, expand market share, and consolidate resources.

In addition, many market participants are focusing on regional expansion to tap into emerging markets and strengthen their foothold in existing territories. This geographic growth strategy enables companies to access new customer bases and better serve diverse global markets, thereby increasing their overall competitive advantage.

Another important approach involves diversifying product portfolios. By broadening their range of offerings, companies are better equipped to address the needs of a wider variety of applications across different industries. This diversification includes the development of specialized mass spectrometry systems that are tailored to meet the unique requirements of specific sectors such as pharmaceuticals, biotechnology, environmental testing, food safety, and clinical diagnostics. Such targeted solutions help companies differentiate themselves and better cater to the precise demands of niche markets, further intensifying competition in the industry.

Key Players

• Thermo Fisher Scientific, Inc.

• Agilent Technologies, Inc.

• Danaher Corporation (SCIEX)

• Waters Corporation

• Bruker Corporation

• Shimadzu Corporation

• PerkinElmer, Inc.

• Rigaku Corporation

• LECO Corporation

• JEOL Ltd.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global mass spectrometry market is poised for significant growth, driven by increasing investments in pharmaceutical and biotechnology research and development. Technological advancements, such as the integration of artificial intelligence for data analysis and the development of high-resolution mass spectrometers, are enhancing the capabilities of mass spectrometry in complex sample analysis. Additionally, the growing applications of mass spectrometry in proteomics and biomedical research are contributing to its expanding role in scientific discovery and diagnostics.